Tauheed Ishrat
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Tauheed Ishrat has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
Bindu Pillai
Univ of Georgia, College of Pharmacy, Augusta, GA
7 shared publications- Abdelrahman Y. Fouda
Department of Pharmacology & Toxicology, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA
4 shared publications Adviye Ergul
Charlie Norwood VA Medical Center
4 shared publications- Adviye Ergul
Medical University of South Carolina
4 shared publications - Jennifer L. Waller
Department of Family and Community Medicine, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA
3 shared publications Sahar Soliman
Charlie Norwood VA Medical Center
3 shared publications
Latest Publications
- Open Access
- 13 August 2018
- Published byĀ Springer NatureĀ inĀ Journal of Neuroinflammation
- Vol.Ā 15 Ā (1) , 1-16
RAS modulation prevents progressive cognitive impairment after experimental stroke: a randomized, blinded preclinical trial
With the aging population, the prevalence and incidence of cerebrovascular disease will continue to rise, as well as the number of individuals with vascular cognitive impairment/dementia (VCID). No specific FDA-approved treatments for VCID exist. Although clinical evidence supports that angiotensin receptor blockers (ARBs) prevent cognitive decline in older adults, whether ARBs have a similar effect on VCID after stroke is unknown. Moreover, these agents reduce BP, which is undesirable in the acute stroke period, so we believe that giving C21 in this acute phase or delaying ARB administration would enable us to achieve the neurovascular benefits without the risk of unintended and potentially dangerous, acute BP lowering. The aim of our study was to determine the impact of candesartan (ARB) or compound-21 (an angiotensin type 2 receptorāāAT2Rāāagonist) on long-term cognitive function post-stroke, in spontaneously hypertensive rats (SHRs). We hypothesized that AT2R stimulation, either directly with C21, or indirectly by blocking the angiotensin type 1 receptor (AT1R) with candesartan, initiated after stroke, would reduce cognitive impairment. Animals were subjected to a 60-min transient middle cerebral artery occlusion and randomly assigned to either saline/C21 monotherapy, for the full study duration (30 days), or given sequential therapy starting with saline/C21 (7 days) followed by candesartan for the remainder of the study (21 days). Outcome measures included sensorimotor/cognitive-function, amyloid-β determination, and histopathologic analyses. Treatment with RAS modulators effectively preserved cognitive function, reduced cytotoxicity, and prevented chronic-reactive microgliosis in SHRs, post-stroke. These protective effects were apparent even when treatment was delayed up to 7 days post-stroke and were independent of blood pressure and β-amyloid accumulation. Collectively, our findings demonstrate that RAS modulators effectively prevent cognitive impairment after stroke, even when treatment is delayed.
- 13 August 2018
- Published byĀ Springer NatureĀ inĀ Journal of Neuroinflammation
- Vol.Ā 15 Ā (1) , 1-16
Open AccessRAS modulation prevents progressive cognitive impairment after experimental stroke: a randomized, blinded preclinical trial
With the aging population, the prevalence and incidence of cerebrovascular disease will continue to rise, as well as the number of individuals with vascular cognitive impairment/dementia (VCID). No specific FDA-approved treatments for VCID exist. Although clinical evidence supports that angiotensin receptor blockers (ARBs) prevent cognitive decline in older adults, whether ARBs have a similar effect on VCID after stroke is unknown. Moreover, these agents reduce BP, which is undesirable in the acute stroke period, so we believe that giving C21 in this acute phase or delaying ARB administration would enable us to achieve the neurovascular benefits without the risk of unintended and potentially dangerous, acute BP lowering. The aim of our study was to determine the impact of candesartan (ARB) or compound-21 (an angiotensin type 2 receptorāāAT2Rāāagonist) on long-term cognitive function post-stroke, in spontaneously hypertensive rats (SHRs). We hypothesized that AT2R stimulation, either directly with C21, or indirectly by blocking the angiotensin type 1 receptor (AT1R) with candesartan, initiated after stroke, would reduce cognitive impairment. Animals were subjected to a 60-min transient middle cerebral artery occlusion and randomly assigned to either saline/C21 monotherapy, for the full study duration (30 days), or given sequential therapy starting with saline/C21 (7 days) followed by candesartan for the remainder of the study (21 days). Outcome measures included sensorimotor/cognitive-function, amyloid-β determination, and histopathologic analyses. Treatment with RAS modulators effectively preserved cognitive function, reduced cytotoxicity, and prevented chronic-reactive microgliosis in SHRs, post-stroke. These protective effects were apparent even when treatment was delayed up to 7 days post-stroke and were independent of blood pressure and β-amyloid accumulation. Collectively, our findings demonstrate that RAS modulators effectively prevent cognitive impairment after stroke, even when treatment is delayed.
- 22 January 2018
- Published byĀ Wolters Kluwer HealthĀ inĀ Stroke
- Vol.Ā 49 Ā (Suppl_1)
Abstract TP88: Delayed Therapeutic Window for Prevention of Progressive Cognitive Impairment After Experimental Stroke
Background: With the aging population, the prevalence and incidence of cerebrovascular disease will continue to rise, as will the number of individuals with post-stroke cognitive impairment (PSCI). Unfortunately, no specific FDA approved treatments for PSCI exist. Although clinical trial evidence supports that renin angiotensin system (RAS) modulation by angiotensin receptor blockers (ARBs) prevent cognitive decline in older adults. The aim of our study was to determine the impact of the ARB candesartan or the AT2R agonist, C21, after stroke, on long-term cognitive function in spontaneously hypertensive rats (SHRs). Methods: Thirty three SHRs were subjected to a 60 minute transient middle cerebral artery occlusion (MCAO) and randomly assigned to either Saline/ C21 (0.3 mg/kg, IP) only or Saline/ C21 (7 days) followed by candesartan (0.3 mg/kg) IP for the remainder of the study. Outcome measures included sensorimotor and cognitive function, performed using a sequence of blinded tests, and assessed at baseline and up to 28 days post-stroke. Animals were sacrificed at 30 days and their brains collected for amyloid-β protein determination and histopathologic analyses. Results: Chronic administration of C21, or candesartan prevented PSCI, even when treatment was initiated at 7 days after the ischemic insult. The groups treated with C21 and candesartan demonstrated superior performance on the novel NOR test, compared to saline treated animals. C21 (first 7 days) only or C2 and candesartan treatments had markedly lower hippocampal concentrations of Aβ1-42 at 30 days post-stroke than those treated with saline. Sensorimotor deficits (Bederson and beam walk scores) were pronounced at 24 h post-stroke and all treatment groups showed similar recovery at 28 days post stroke. C21 had no effect on BP compared to saline-treated controls. Conclusion: Collectively, our findings demonstrate that RAS modulators effectively prevent PSCI, even when treatment is delayed.
- 22 January 2018
- Published byĀ Wolters Kluwer HealthĀ inĀ Stroke
- Vol.Ā 49 Ā (Suppl_1)
Abstract TP88: Delayed Therapeutic Window for Prevention of Progressive Cognitive Impairment After Experimental Stroke
Background: With the aging population, the prevalence and incidence of cerebrovascular disease will continue to rise, as will the number of individuals with post-stroke cognitive impairment (PSCI). Unfortunately, no specific FDA approved treatments for PSCI exist. Although clinical trial evidence supports that renin angiotensin system (RAS) modulation by angiotensin receptor blockers (ARBs) prevent cognitive decline in older adults. The aim of our study was to determine the impact of the ARB candesartan or the AT2R agonist, C21, after stroke, on long-term cognitive function in spontaneously hypertensive rats (SHRs). Methods: Thirty three SHRs were subjected to a 60 minute transient middle cerebral artery occlusion (MCAO) and randomly assigned to either Saline/ C21 (0.3 mg/kg, IP) only or Saline/ C21 (7 days) followed by candesartan (0.3 mg/kg) IP for the remainder of the study. Outcome measures included sensorimotor and cognitive function, performed using a sequence of blinded tests, and assessed at baseline and up to 28 days post-stroke. Animals were sacrificed at 30 days and their brains collected for amyloid-β protein determination and histopathologic analyses. Results: Chronic administration of C21, or candesartan prevented PSCI, even when treatment was initiated at 7 days after the ischemic insult. The groups treated with C21 and candesartan demonstrated superior performance on the novel NOR test, compared to saline treated animals. C21 (first 7 days) only or C2 and candesartan treatments had markedly lower hippocampal concentrations of Aβ1-42 at 30 days post-stroke than those treated with saline. Sensorimotor deficits (Bederson and beam walk scores) were pronounced at 24 h post-stroke and all treatment groups showed similar recovery at 28 days post stroke. C21 had no effect on BP compared to saline-treated controls. Conclusion: Collectively, our findings demonstrate that RAS modulators effectively prevent PSCI, even when treatment is delayed.
- 22 January 2018
- Published byĀ Wolters Kluwer HealthĀ inĀ Stroke
- Vol.Ā 49 Ā (Suppl_1)
Abstract TP100: Angiotensin Type 2 Receptor Stimulation With Compound 21 Improves Stroke Outcome in Female Rats: Possible Role for Peroxisome Proliferator-activated Receptor Gamma
Introduction: The angiotensin type 2 receptor (AT2R) agonist, compound 21 (C21), has been shown to be neuro-protective, pro-angiogenic and anti-inflammatory after stroke in male rats. Here we aimed to study the effect of C21 treatment on ovary-intact female rats after stroke. Methods: Female Wistar rats were subjected to 3 h middle cerebral artery occlusion (MCAO) using a silicone-coated monofilament and treated at reperfusion with IP C21 0.03 mg/kg. Rats were sacrificed at 24 h and brains collected for infarct analysis. Another cohort of female rats were subjected to MCAO and treated at reperfusion with C21 for 2 days. Animals were followed up and sacrificed at 72 h. Behavioral tests (Bederson, Paw grasp, Beam walk and Rotarod) were performed at 24 h and 72 h, and whole brains were collected for western blotting. Results (mean±SEM): C21 treatment in females resulted in a decrease in infarct size, improvement in Bederson, Paw grasp and rotarod scores. Interestingly, C21 treatment showed a trend toward increased expression of the transcription factor PPARγ at 72 h in sham and stroked animals suggesting a novel crosstalk between the AT2R and PPARγ after ischemic stroke. In addition, stroke surgery resulted in a decrease in the AT2R expression. However, sham treated animals had an increase in the AT2R expression. Conclusions: AT2R stimulation using C21 improves stroke outcome in ovary-intact female rats.
- 22 January 2018
- Published byĀ Wolters Kluwer HealthĀ inĀ Stroke
- Vol.Ā 49 Ā (Suppl_1)
Abstract TP100: Angiotensin Type 2 Receptor Stimulation With Compound 21 Improves Stroke Outcome in Female Rats: Possible Role for Peroxisome Proliferator-activated Receptor Gamma
Introduction: The angiotensin type 2 receptor (AT2R) agonist, compound 21 (C21), has been shown to be neuro-protective, pro-angiogenic and anti-inflammatory after stroke in male rats. Here we aimed to study the effect of C21 treatment on ovary-intact female rats after stroke. Methods: Female Wistar rats were subjected to 3 h middle cerebral artery occlusion (MCAO) using a silicone-coated monofilament and treated at reperfusion with IP C21 0.03 mg/kg. Rats were sacrificed at 24 h and brains collected for infarct analysis. Another cohort of female rats were subjected to MCAO and treated at reperfusion with C21 for 2 days. Animals were followed up and sacrificed at 72 h. Behavioral tests (Bederson, Paw grasp, Beam walk and Rotarod) were performed at 24 h and 72 h, and whole brains were collected for western blotting. Results (mean±SEM): C21 treatment in females resulted in a decrease in infarct size, improvement in Bederson, Paw grasp and rotarod scores. Interestingly, C21 treatment showed a trend toward increased expression of the transcription factor PPARγ at 72 h in sham and stroked animals suggesting a novel crosstalk between the AT2R and PPARγ after ischemic stroke. In addition, stroke surgery resulted in a decrease in the AT2R expression. However, sham treated animals had an increase in the AT2R expression. Conclusions: AT2R stimulation using C21 improves stroke outcome in ovary-intact female rats.
- 22 January 2018
- Published byĀ Wolters Kluwer HealthĀ inĀ Stroke
- Vol.Ā 49 Ā (Suppl_1)
Abstract TP89: Angiotensin Receptor (AT2R) Agonist C21 Accelerates Cognitive Functional Recovery After Permanent Stroke in Aged Animals
Background and objectives: Post stroke cognitive impairment (PSCI) is an understudied, long-term complication of stroke, impacting nearly 30-40% of all stroke survivors. No cure is available once the cognitive deterioration manifests. Compound 21 (C21), a novel selective non-peptide angiotensin receptor (AT2R) agonist, has also shown therapeutic efficacy in a variety of experimental stroke models, but C21 effect on PSCI model is lacking. To our knowledge, this is the first study to investigate the long-term effects of C21 treatment on the development of PSCI in aged animals. Methods: Distal docal cerebral ischemia was induced in 14-month-old male Wistar rats by direct electro-coagulation of middle cerebral artery for permanent occlusion (pMCAO). Animals were randomly assigned to receive either C21 or vehicle which was initiated the following day, and continued for a total of 30 days (0.12 mg/kg/d, orally). Outcome measures for sensorimotor and cognitive function were performed using a sequence of tests, all blindly conducted and assessed at baseline as well as at different time points post-pMCAO. Repeated measures ANOVA mixed models were used to examine differences in behavioral outcomes. Results: C21 reduced weight loss and enhanced recovery (Table). Treatment with C21 showed significant improvement in non-spatial and short-term working memory compared to vehicle. Moreover, C21 preserved reference memory and facilitated associative learning compared to vehicle treated rats after pMCAO. Further, C21 prevented Aβ 1-42 . C21 did not show any effect on motor deficits score compared to vehicle. Conclusion: Our findings demonstrate that the angiotensin receptor (AT2R) agonist C21 effectively preserves cognitive function and prevents the development of PSCI in aged animals.
- 22 January 2018
- Published byĀ Wolters Kluwer HealthĀ inĀ Stroke
- Vol.Ā 49 Ā (Suppl_1)
Abstract TP89: Angiotensin Receptor (AT2R) Agonist C21 Accelerates Cognitive Functional Recovery After Permanent Stroke in Aged Animals
Background and objectives: Post stroke cognitive impairment (PSCI) is an understudied, long-term complication of stroke, impacting nearly 30-40% of all stroke survivors. No cure is available once the cognitive deterioration manifests. Compound 21 (C21), a novel selective non-peptide angiotensin receptor (AT2R) agonist, has also shown therapeutic efficacy in a variety of experimental stroke models, but C21 effect on PSCI model is lacking. To our knowledge, this is the first study to investigate the long-term effects of C21 treatment on the development of PSCI in aged animals. Methods: Distal docal cerebral ischemia was induced in 14-month-old male Wistar rats by direct electro-coagulation of middle cerebral artery for permanent occlusion (pMCAO). Animals were randomly assigned to receive either C21 or vehicle which was initiated the following day, and continued for a total of 30 days (0.12 mg/kg/d, orally). Outcome measures for sensorimotor and cognitive function were performed using a sequence of tests, all blindly conducted and assessed at baseline as well as at different time points post-pMCAO. Repeated measures ANOVA mixed models were used to examine differences in behavioral outcomes. Results: C21 reduced weight loss and enhanced recovery (Table). Treatment with C21 showed significant improvement in non-spatial and short-term working memory compared to vehicle. Moreover, C21 preserved reference memory and facilitated associative learning compared to vehicle treated rats after pMCAO. Further, C21 prevented Aβ 1-42 . C21 did not show any effect on motor deficits score compared to vehicle. Conclusion: Our findings demonstrate that the angiotensin receptor (AT2R) agonist C21 effectively preserves cognitive function and prevents the development of PSCI in aged animals.
- Open Access
- 1 January 2015
- Published byĀ Central Council for Research in HomoeopathyĀ inĀ Indian Journal of Research in Homoeopathy
- Vol.Ā 9 Ā (2) , 86
Protective effect of Zincum metallicum on rat model of Parkinsonā²s disease
Background: Parkinson's Disease (PD) is one of the major neurodegenerative disorders, and oxidative stress has been implicated in playing an important role in the pathogenesis of the disease. Zincum metallicum, produces symptoms mentioned in Homoeopathic Materia Medica which are akin to PD on which basis it might be considered as one at the intermediate to treat the disease. Materials and Methods: Rats were divided into eight groups; surgery was done by stereotaxic apparatus. 6 - hydroxydopamine was used to induce parkinsonism thereafter on 16 th day of lesioning animals were assessed by the video path analyzer. Animals were sacrificed and biochemical assays (Lipid peroxidation [LPO], glutathione [GSH], glutathione peroxide [GPx], glutathione reductase [GR], glutathione-S-transferase [GST]) and level of dopamine (DA), 3,4-dihydroxyphenylacetic acid (DOPAC), and homovanillic acid (HVA), were estimated. Further dopaminergic D 2 receptor binding was also done to confirm the induced parkinsonism. Results: The behavior activities (locomotor, distance travel, stereroevent) were decreased whereas the rest time was increased in lesion group animals as compared to the sham group. The locomotor activity and the distance traveled were protected significantly with 6C whereas rest time was protected significantly with 30C and 200C of Homoeopathic medicine Zincum metallicum. On the other hand, S + 30C and S + 200C groups have shown increased locomotor activities as compared to S group. The rest time was also increased significantly in S + 6C and S + 30C group animals as compared to S group. The elevated level of LPO and DA D 2 receptor binding density in PD group was protected significantly with Zincum metallicum (6C, 30C, and 200C). The depleted level of GSH and activity of antioxidant enzymes (GPx, GR, and GST) and DA and its metabolites DOPAC and HVA were protected significantly with Zincum metallicum (6C, 30C, and 200C). Conclusion: The study indicates the Zincum metallicum may be helpful in slowing down injury in parkinsonism and could be a beneficial drug for the prevention of PD.
- 1 January 2015
- Published byĀ Central Council for Research in HomoeopathyĀ inĀ Indian Journal of Research in Homoeopathy
- Vol.Ā 9 Ā (2) , 86
Open AccessProtective effect of Zincum metallicum on rat model of Parkinsonā²s disease
Background: Parkinson's Disease (PD) is one of the major neurodegenerative disorders, and oxidative stress has been implicated in playing an important role in the pathogenesis of the disease. Zincum metallicum, produces symptoms mentioned in Homoeopathic Materia Medica which are akin to PD on which basis it might be considered as one at the intermediate to treat the disease. Materials and Methods: Rats were divided into eight groups; surgery was done by stereotaxic apparatus. 6 - hydroxydopamine was used to induce parkinsonism thereafter on 16 th day of lesioning animals were assessed by the video path analyzer. Animals were sacrificed and biochemical assays (Lipid peroxidation [LPO], glutathione [GSH], glutathione peroxide [GPx], glutathione reductase [GR], glutathione-S-transferase [GST]) and level of dopamine (DA), 3,4-dihydroxyphenylacetic acid (DOPAC), and homovanillic acid (HVA), were estimated. Further dopaminergic D 2 receptor binding was also done to confirm the induced parkinsonism. Results: The behavior activities (locomotor, distance travel, stereroevent) were decreased whereas the rest time was increased in lesion group animals as compared to the sham group. The locomotor activity and the distance traveled were protected significantly with 6C whereas rest time was protected significantly with 30C and 200C of Homoeopathic medicine Zincum metallicum. On the other hand, S + 30C and S + 200C groups have shown increased locomotor activities as compared to S group. The rest time was also increased significantly in S + 6C and S + 30C group animals as compared to S group. The elevated level of LPO and DA D 2 receptor binding density in PD group was protected significantly with Zincum metallicum (6C, 30C, and 200C). The depleted level of GSH and activity of antioxidant enzymes (GPx, GR, and GST) and DA and its metabolites DOPAC and HVA were protected significantly with Zincum metallicum (6C, 30C, and 200C). Conclusion: The study indicates the Zincum metallicum may be helpful in slowing down injury in parkinsonism and could be a beneficial drug for the prevention of PD.
- 11 December 2014
- Published byĀ Springer NatureĀ inĀ Molecular Neurobiology
- Vol.Ā 51 Ā (2) , 779-780
Erratum to: Thioredoxin-Interacting Protein: a Novel Target for Neuroprotection in Experimental Thromboembolic Stroke in Mice
- 11 December 2014
- Published byĀ Springer NatureĀ inĀ Molecular Neurobiology
- Vol.Ā 51 Ā (2) , 779-780
Erratum to: Thioredoxin-Interacting Protein: a Novel Target for Neuroprotection in Experimental Thromboembolic Stroke in Mice
- 2 August 2014
- Published byĀ Springer NatureĀ inĀ Molecular Neurobiology
- Vol.Ā 51 Ā (3) , 1542-1553
Low-Dose Candesartan Enhances Molecular Mediators of Neuroplasticity and Subsequent Functional Recovery After Ischemic Stroke in Rats
We have previously reported that angiotensin type 1 receptor (AT1R) blockade with candesartan exerts neurovascular protection after experimental cerebral ischemia. Here, we tested the hypothesis that a low, subhypotensive dose of candesartan enhances neuroplasticity and subsequent functional recovery through enhanced neurotrophic factor expression in rats subjected to ischemia reperfusion injury. Male Wistar rats (290ā300 g) underwent 90 min of middle cerebral artery occlusion (MCAO) and received candesartan (0.3 mg/kg) or saline at reperfusion and then once every 24 h for 7 days. Functional deficits were assessed in a blinded manner at 1, 3, 7, and 14 days after MCAO. Animals were sacrificed 14-day post-stroke and the brains perfused for infarct size by cresyl violet. Western blot and immunohistochemistry were used to assess the expression of growth factors and synaptic proteins. Candesartan-treated animals showed a significant reduction in the infarct size [t (13) = ā5.5, P = 0.0001] accompanied by functional recovery in Bederson [F (1, 13) = 7.9, P = 0.015], beam walk [F (1, 13) = 6.7, P = 0.023], grip strength [F (1, 13) = 15.2, P = 0.0031], and rotarod performance [F (1, 14) = 29.8, P < 0.0001]. In addition, candesartan-treated animals showed significantly higher expression of active metalloproteinase-3 (MMP-3), laminin, and angiopoietin-1 (Ang-1). The expression of vascular endothelial growth factor (VEGF) and brain-derived neurotrophic factor (BDNF) and its receptor was significantly increased in the animals treated with candesartan. Also, we observed significant increases in neuroplasticity markers, synaptophysin, and PSD-95. These results indicate that low-dose candesartan had a large and enduring effect on measures of plasticity, and this accompanied the functional recovery after ischemic stroke.
- 2 August 2014
- Published byĀ Springer NatureĀ inĀ Molecular Neurobiology
- Vol.Ā 51 Ā (3) , 1542-1553
Low-Dose Candesartan Enhances Molecular Mediators of Neuroplasticity and Subsequent Functional Recovery After Ischemic Stroke in Rats
We have previously reported that angiotensin type 1 receptor (AT1R) blockade with candesartan exerts neurovascular protection after experimental cerebral ischemia. Here, we tested the hypothesis that a low, subhypotensive dose of candesartan enhances neuroplasticity and subsequent functional recovery through enhanced neurotrophic factor expression in rats subjected to ischemia reperfusion injury. Male Wistar rats (290ā300 g) underwent 90 min of middle cerebral artery occlusion (MCAO) and received candesartan (0.3 mg/kg) or saline at reperfusion and then once every 24 h for 7 days. Functional deficits were assessed in a blinded manner at 1, 3, 7, and 14 days after MCAO. Animals were sacrificed 14-day post-stroke and the brains perfused for infarct size by cresyl violet. Western blot and immunohistochemistry were used to assess the expression of growth factors and synaptic proteins. Candesartan-treated animals showed a significant reduction in the infarct size [t (13) = ā5.5, P = 0.0001] accompanied by functional recovery in Bederson [F (1, 13) = 7.9, P = 0.015], beam walk [F (1, 13) = 6.7, P = 0.023], grip strength [F (1, 13) = 15.2, P = 0.0031], and rotarod performance [F (1, 14) = 29.8, P < 0.0001]. In addition, candesartan-treated animals showed significantly higher expression of active metalloproteinase-3 (MMP-3), laminin, and angiopoietin-1 (Ang-1). The expression of vascular endothelial growth factor (VEGF) and brain-derived neurotrophic factor (BDNF) and its receptor was significantly increased in the animals treated with candesartan. Also, we observed significant increases in neuroplasticity markers, synaptophysin, and PSD-95. These results indicate that low-dose candesartan had a large and enduring effect on measures of plasticity, and this accompanied the functional recovery after ischemic stroke.
- 18 June 2014
- Published byĀ Springer NatureĀ inĀ Molecular Neurobiology
- Vol.Ā 51 Ā (2) , 766-778
Thioredoxin-Interacting Protein: a Novel Target for Neuroprotection in Experimental Thromboembolic Stroke in Mice
Redox imbalance in the brain significantly contributes to ischemic stroke pathogenesis, but antioxidant therapies have failed in clinical trials. Activation of endogenous defense mechanisms may provide better protection against stroke-induced oxidative injury. TXNIP (thioredoxin-interacting protein) is an endogenous inhibitor of thioredoxin (TRX), a key antioxidant system. We hypothesize that TXNIP inhibition attenuates redox imbalance and inflammation and provides protection against a clinically relevant model of embolic stroke. Male TXNIP-knockout (TKO), wild-type (WT), and WT mice treated with a pharmacological inhibitor of TXNIP, resveratrol (RES; 5 mg/kg body weight), were subjected to embolic middle cerebral artery occlusion (eMCAO). Behavior outcomes were monitored using neurological deficits score and grip strength meter at 24 h after eMCAO. Expression of oxidative, inflammatory, and apoptotic markers was analyzed by Western blot, immunohistochemistry, and slot blot at 24 h post-eMCAO. Our result showed that ischemic injury increases TXNIP in WT mice and that RES inhibits TXNIP expression and protects the brain against ischemic damage. TKO and RES-treated mice exhibited a 39.26 and 41.11 % decrease in infarct size and improved neurological score and grip strength compared to WT mice after eMCAO. Furthermore, the levels of TRX, nitrotyrosine, NOD-like receptor protein (NLRP3), interleukin-1β (IL-1β), tumor necrosis factor-α (TNF-α), and activations of caspase-1, caspase-3, and poly-ADP-ribose polymerase (PARP) were significantly (P < 0.05) attenuated in TKO and RES-treated mice. The present study suggests that TXNIP is contributing to acute ischemic stroke through redox imbalance and inflammasome activation and inhibition of TXNIP may provide a new target for therapeutic interventions. This study also affirms the importance of the antioxidant effect of RES on the TRX/TXNIP system.
- 18 June 2014
- Published byĀ Springer NatureĀ inĀ Molecular Neurobiology
- Vol.Ā 51 Ā (2) , 766-778
Thioredoxin-Interacting Protein: a Novel Target for Neuroprotection in Experimental Thromboembolic Stroke in Mice
Redox imbalance in the brain significantly contributes to ischemic stroke pathogenesis, but antioxidant therapies have failed in clinical trials. Activation of endogenous defense mechanisms may provide better protection against stroke-induced oxidative injury. TXNIP (thioredoxin-interacting protein) is an endogenous inhibitor of thioredoxin (TRX), a key antioxidant system. We hypothesize that TXNIP inhibition attenuates redox imbalance and inflammation and provides protection against a clinically relevant model of embolic stroke. Male TXNIP-knockout (TKO), wild-type (WT), and WT mice treated with a pharmacological inhibitor of TXNIP, resveratrol (RES; 5 mg/kg body weight), were subjected to embolic middle cerebral artery occlusion (eMCAO). Behavior outcomes were monitored using neurological deficits score and grip strength meter at 24 h after eMCAO. Expression of oxidative, inflammatory, and apoptotic markers was analyzed by Western blot, immunohistochemistry, and slot blot at 24 h post-eMCAO. Our result showed that ischemic injury increases TXNIP in WT mice and that RES inhibits TXNIP expression and protects the brain against ischemic damage. TKO and RES-treated mice exhibited a 39.26 and 41.11 % decrease in infarct size and improved neurological score and grip strength compared to WT mice after eMCAO. Furthermore, the levels of TRX, nitrotyrosine, NOD-like receptor protein (NLRP3), interleukin-1β (IL-1β), tumor necrosis factor-α (TNF-α), and activations of caspase-1, caspase-3, and poly-ADP-ribose polymerase (PARP) were significantly (P < 0.05) attenuated in TKO and RES-treated mice. The present study suggests that TXNIP is contributing to acute ischemic stroke through redox imbalance and inflammasome activation and inhibition of TXNIP may provide a new target for therapeutic interventions. This study also affirms the importance of the antioxidant effect of RES on the TRX/TXNIP system.
- Open Access
- 1 January 2014
- Published byĀ WileyĀ inĀ Stroke Research and Treatment
- Vol.Ā 2014, 1-9
Role of Matrix Metalloproteinase Activity in the Neurovascular Protective Effects of Angiotensin Antagonism
Background and Purpose. Oxidative stress and matrix metalloproteinase (MMP) activity have been identified as key mediators of early vascular damage after ischemic stroke. Somewhat surprisingly, the angiotensin II type 1 receptor (AT1) blocker, candesartan, has been shown to acutely increase MMP activity while providing neurovascular protection. We aimed to determine the contribution of MMP and nitrative stress to the effects of angiotensin blockade in experimental stroke.Methods. Wistar rats (n = 9–14/group; a total of 99) were treated in a factorial design with candesartan 1 mg/kg IV, alone or in combination with either a peroxynitrite decomposition catalyst, FeTPPs, 30 mg/kg IP or GM6001 50 mg/kg IP (MMP inhibitor). Neurological deficit, infarct, size and hemorrhagic transformation (HT) were measured after 3 h of middle cerebral artery occlusion (MCAO) and 21 h of reperfusion. MMP activity and nitrotyrosine expression were also measured.Results. Candesartan reduced infarct size and HT when administered alone () and in combination with FeTPPs (). GM6001 did not significantly affect HT when administered alone, but the combination with candesartan caused increased HT () and worsened neurologic score ().Conclusions. Acute administration of candesartan reduces injury after stroke despite increasing MMP activity, likely by an antioxidant mechanism.- 1 January 2014
- Published byĀ WileyĀ inĀ Stroke Research and Treatment
- Vol.Ā 2014, 1-9
Open AccessRole of Matrix Metalloproteinase Activity in the Neurovascular Protective Effects of Angiotensin Antagonism
Background and Purpose. Oxidative stress and matrix metalloproteinase (MMP) activity have been identified as key mediators of early vascular damage after ischemic stroke. Somewhat surprisingly, the angiotensin II type 1 receptor (AT1) blocker, candesartan, has been shown to acutely increase MMP activity while providing neurovascular protection. We aimed to determine the contribution of MMP and nitrative stress to the effects of angiotensin blockade in experimental stroke.Methods. Wistar rats (n = 9–14/group; a total of 99) were treated in a factorial design with candesartan 1 mg/kg IV, alone or in combination with either a peroxynitrite decomposition catalyst, FeTPPs, 30 mg/kg IP or GM6001 50 mg/kg IP (MMP inhibitor). Neurological deficit, infarct, size and hemorrhagic transformation (HT) were measured after 3 h of middle cerebral artery occlusion (MCAO) and 21 h of reperfusion. MMP activity and nitrotyrosine expression were also measured.Results. Candesartan reduced infarct size and HT when administered alone () and in combination with FeTPPs (). GM6001 did not significantly affect HT when administered alone, but the combination with candesartan caused increased HT () and worsened neurologic score ().Conclusions. Acute administration of candesartan reduces injury after stroke despite increasing MMP activity, likely by an antioxidant mechanism. - 1 July 2009
- Published byĀ ElsevierĀ inĀ Brain Research
- Vol.Ā 1281, 117-127
Selenium prevents cognitive decline and oxidative damage in rat model of streptozotocin-induced experimental dementia of Alzheimer's type
- 1 July 2009
- Published byĀ ElsevierĀ inĀ Brain Research
- Vol.Ā 1281, 117-127
Selenium prevents cognitive decline and oxidative damage in rat model of streptozotocin-induced experimental dementia of Alzheimer's type